AnaptysBio (ANAB) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AnaptysBio (ANAB) has outperformed Nanobiotix S.A. (NBTX) over the past year, gaining 129.2% versus a gain of 17.4%. Over five years, ANAB leads with a +138.8% price change compared with +92.0% for NBTX. AnaptysBio is the larger company by market cap ($1.38 billion vs $1.17 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | NBTX |
|---|---|---|
| Share price | $46.21 | $22.90 |
| Market cap | $1.38B | $1.17B |
| 1-day change | +1.23% | -6.99% |
| YTD return | +41.24% | +6.49% |
| 1-year return | +129.24% | +17.41% |
| 5-year return | +138.84% | +92.04% |
| Forward P/E | 9.12 | — |
| EPS (TTM) | $-0.96 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $57.14 |
| 52-week low | $20.18 | $14.78 |
| Distance from 52-week high | -36.14% | -59.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.81% | +135.28% |
| Average volume | 563.32K | 148.97K |
| Shares outstanding | 29.90M | 50.92M |
| Employees | — | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed NBTX by 111.8 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ANAB vs NBTX FAQ
Which is bigger, AnaptysBio or Nanobiotix S.A.?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.38B compared with $1.17B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, ANAB or NBTX?
ANAB returned +129.24% over the past 12 months, compared with +17.41% for NBTX (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Nanobiotix S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.